Literature DB >> 9225046

Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.

I Jochmus1, W Osen, A Altmann, G Buck, B Hofmann, A Schneider, L Gissmann, H G Rammensee.   

Abstract

In order to establish tumour-specific cytotoxic T lymphocyte (CTL) cell lines, T cells from a human papillomavirus (HPV) type 16-positive patient with a cervical carcinoma in situ and from a healthy volunteer were stimulated in vitro with autologous dendritic cells loaded with peptides derived from the viral transforming proteins E6 and E7 and corresponding to potential HLA-A*0201-restricted T cell epitopes. From each donor a small number of low-affinity CTL lines against the peptide E7/86-93 was obtained, which specifically lysed HLA-A*0201-expressing B-lymphocytes (cell line 721) loaded with this peptide. Cytotoxicity was also observed against two HLA-A*0201-E7-positive epithelial cell lines, the cervical carcinoma cell line CaSki and the HPV-16-immortalized foreskin-keratinocyte cell line HPK IA. However, since none of the CTL recognized both cell lines, and E7-expressing 721 transfectants were never lysed, it was concluded that the reactivity against CaSki and HPK IA cells was due to cross-reactivity on allogeneic HLA molecules rather than to E7 recognition, which emphasizes that the specificity of tumour cell lysis by peptide-induced CTL has to be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9225046     DOI: 10.1099/0022-1317-78-7-1689

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Influenza virus-infected epithelial cells present viral antigens to antigen-specific CD8+ cytotoxic T lymphocytes.

Authors:  H H Nguyen; P N Boyaka; Z Moldoveanu; M J Novak; H Kiyono; J R McGhee; J Mestecky
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.

Authors:  A D Santin; P L Hermonat; A Ravaggi; M Chiriva-Internati; D Zhan; S Pecorelli; G P Parham; M J Cannon
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 5.  Immunotherapy for HPV Malignancies.

Authors:  Maxwell Y Lee; Clint T Allen
Journal:  Semin Radiat Oncol       Date:  2021-10       Impact factor: 5.421

6.  Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.

Authors:  Kirsten B J Scholten; Annelies W Turksma; Janneke J Ruizendaal; Muriel van den Hende; Sjoerd H van der Burg; Mirjam H M Heemskerk; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2011-09-05       Impact factor: 5.531

7.  A microarray method for identifying tumor antigens by screening a tumor cDNA expression library against cancer sera.

Authors:  Kurt Whittemore; Kathryn Sykes
Journal:  Hum Vaccin Immunother       Date:  2013-07-12       Impact factor: 3.452

8.  Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.

Authors:  Sunghoon Kim; Hye Won Chung; Hoon Young Kong; Jong Baeck Lim
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

9.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

10.  A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.

Authors:  Massimiliano Bissa; Elena Illiano; Sole Pacchioni; Francesca Paolini; Carlo Zanotto; Carlo De Giuli Morghen; Silvia Massa; Rosella Franconi; Antonia Radaelli; Aldo Venuti
Journal:  J Transl Med       Date:  2015-03-05       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.